Venkat Reddy Y

Venkat Reddy Y has a diverse and extensive work history. Venkat Reddy started their career as a Production Supervisor at Dr Reddys Laboratories in 1996, where they were responsible for API tech transfers and commercial manufacturing. Venkat Reddy then worked as an Executive in Regulatory Affairs and Quality Assurance at Hetero Drugs Ltd for a short period before joining Schering Plough Singapore in 2001 as a Senior Regulatory Specialist. At Schering Plough Singapore, they were part of a pioneer team setting up a new biotech facility and played a crucial role in navigating commercial products from a regulatory standpoint.

In 2005, Venkat joined Schering-Plough Research Institute in New Jersey as a CMC Manager, where they served as a Principal Scientist. Venkat Reddy then moved to Bayer HealthCare Pharmaceuticals as an Assistant Director of Regulatory Affairs (CMC) in 2009, taking on responsibilities for regulatory aspects of investigational and marketed products.

In 2011, Venkat joined ImClone Systems, a subsidiary of Eli Lilly and Company, as an Associate Director of Global Regulatory Affairs-CMC. In this role, they had regulatory responsibilities for biological mAb's projects and managed global marketing applications.

Most recently, Venkat has been the Managing Director of GeneSys Biologics since 2015. In this role, they lead the development and execution of the company's long-term strategy, formulating a clear vision and direction. Venkat Reddy is also responsible for building and sustaining a business model that optimizes financing, market, and operational strategies, as well as developing multiple products in-house from bench to market approval.

Venkat Reddy Y obtained a Bachelor of Science (B.Sc.) degree in Industrial Chemistry from Osmania University in 1993. Venkat Reddy subsequently pursued a Master of Science (MS) degree in Industrial Chemistry from Doctor Babasaheb Ambedkar Marathwada University, completing it in 1995. Venkat Reddy Y later pursued a Master of Science (MS) degree in Regulatory Affairs (Drugs, Biologics and Devices) from Northeastern University, Boston, and successfully obtained it in 2011.